10results about "Isotope delivery systems" patented technology

A pierceable plug for closing off a piercing end of a needle is described herein. The plug has an end that is configured to be pierced by the needle to close off the piercing end of the needle. The plug may be radiation sterilizable and may be made of a material that includes an antimicrobial agent. The plug may be used to close off a needle end that is in fluid communication with a radioactive substance.

The application relates to a method for producing medical grade lead-212, including the steps of:a) producing lead-212 by radioactive decay of radium-224 in at least one first chromatography column containing a first stationary phase to which radium-224 is attached;b) eluting thus produced lead-212 from the first stationary phase;c) loading the eluate thus obtained into a second chromatography column containing a second stationary phase to attach the lead-212 to the second stationary phase;d) performing wash(es) of the second stationary phase; and thene) eluting lead-212 from the second stationary phase;and wherein:step b) includes circulating in said at least one first chromatography column an aqueous solution A1 including from 0.8 mol / L to 1.6 mol / L chloride, optionally with at most 200 mmol / L HCl; andstep d) includes circulating in the second chromatography column an aqueous solution A2 including from 0.01 mol / L to 1 mol / L chloride.

The present invention provides a radioisotope generator system with enhanced safety features and implements such system. In particular, the present invention provides a radioisotope generator system comprising a surface that comprises three ports: an evacuation port, a loading port, and a saline flush port. The saline flush port is permanently connected with the loading port so that the rinsing solution can be placed on the saline port and pass it through the Mo-99 vial to minimize the wastage of the Mo-99. The present invention provides a robust design of the three-port radioisotope generator, which is cost-effective and ensures improved safety from needle contamination.

The invention relates to a process for producing medical-grade lead-212, comprising the steps of: a) production of lead-212 by radioactive decay of radium-224 in at least one first chromatography column containing a first stationary phase on which radium-224 is fixed; b) elution of the lead-212 thus produced from the first stationary phase; c) loading of the eluate thus obtained into a second chromatography column containing a second stationary phase to fix the lead-212 on the second stationary phase; d) washing of the second stationary phase; d) elution of the lead-212 from the second stationary phase; and characterized in that: - step b) comprises circulating in said at least one first chromatography column an ​​aqueous solution A1 comprising from 0.8 mol / L to 1.6 mol / L of a chloride, optionally with at most 200 mmol / L of HCl;and- step d) includes circulating an aqueous solution A2 comprising 0.01 mol / L to 1 mol / L of chloride through the second chromatography column. Applications: manufacture of lead-212 based radiopharmaceuticals, useful in nuclear medicine.

The present invention provides a method for separating lead radioisotopes from a mixture comprising lead radioisotopes and radium or thorium radioisotopes, and a system comprising a plurality of chromatography columns. The system can comprise a first cartridge column having a lead complexing medium that preferentially binds lead radioisotopes over radium or thorium radioisotopes; and a second cartridge column having a weak cation exchange medium, wherein the pH of a loading solution used to load the second cartridge column is pH 2L , the pH of an eluent used to elute lead radioisotopes from the second cartridge column is pH 2E , and the pH 2L is greater than pH 2E . The system can further comprise a third cartridge column and a fourth cartridge column having chromatographic media to extract and purify lead radioisotopes, thereby providing a purified solution of lead radioisotopes that can be used for medical and other purposes, such as for labeling radiopharmaceutical compounds.

To provide a method for generating medical-grade lead-212. 【Solution means】The present invention a) generating lead-212 by radioactive decay of radium-224 in at least one first chromatography column containing a first stationary phase to which radium-224 is attached; b) eluting the thus-generated lead-212 from the first stationary phase; c) loading the thus-obtained eluate onto a second chromatography column containing a second stationary phase to attach lead-212 to the second stationary phase; d) performing a washing of the second stationary phase, and e) eluting lead-212 from the second stationary phase In a method for generating medical-grade lead-212, comprising Step b) includes circulating an aqueous solution A1 containing 0.8 mol / L to 1.6 mol / L of chloride, optionally together with up to 200 mmol / L of HCl, through the at least one first chromatography column; Step d) includes circulating an aqueous solution A2 containing 0.01 mol / L to 1 mol / L of chloride through the second chromatography column A method characterized by the above. Use: Manufacture of radiopharmaceuticals based on lead-212 useful in nuclear medicine.

The invention relates to a process for producing medical-grade lead-212, comprising the steps of: a) production of lead-212 by radioactive decay of radium-224 in at least one first chromatography column containing a first stationary phase on which radium-224 is fixed; b) elution of the lead-212 thus produced from the first stationary phase; c) loading of the eluate thus obtained into a second chromatography column containing a second stationary phase to fix the lead-212 on the second stationary phase; d) washing of the second stationary phase; then e) elution of the lead-212 from the second stationary phase; and characterized in that: - step b) comprises circulating in said at least one first chromatography column an ​​aqueous solution A1 comprising from 0.8 mol / L to 1.6 mol / L of a chloride, optionally with at most 200 mmol / L of HCl;and - step d) includes circulating an aqueous solution A2 comprising 0.01 mol / L to 1 mol / L of chloride through the second chromatography column. Applications: manufacture of lead-212 based radiopharmaceuticals, useful in nuclear medicine.

A method for separating a lead radioisotope from a mixture comprising the lead radioisotope and a radioisotope of radium or thorium is provided, along with a system comprising a plurality of chromatographic columns. The system can include a first cartridge having a lead-complexing media that preferentially binds the lead radioisotope over radioisotopes of radium or thorium, and a second cartridge having a weak cationic exchange media, where a pH of a loading solution used to load the second cartridge is pH2L, and a pH of an eluent used to elute the lead radioisotope from the second cartridge is pH2E, and pH2L is greater than pH2E. The system can also comprise further third and fourth cartridges with chromatographic media to extract and purify the lead radioisotope, to provide a purified solution of lead radioisotope that can be used for medical and other purposes, such as in the labeling of radiopharmaceutical compounds.